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Main text
Metformin is the most widely used oral antihyperglyce-
mic agent. Because it is eliminated unmodified in urine,
patients with renal insufficiency can accumulate metfor-
min and may develop lactic acidosis [1]. Recent guide-
lines only restrict the use of metformin in patients with
severe chronic kidney disease (CKD) because the benefit
is considered larger than the risk for lactic acidosis [2].
Lactate measurement has a central role in identifying
and monitoring critical illness [3]. A better understand-
ing of the impact of metformin on lactate levels could
improve clinical assessment of the critically ill.
Data were collected by combining data from Danish
nationwide medical databases with laboratory data [4].
This multicenter cohort included all adults (≥ 18 years)
hospitalized and surviving 24 h of intensive care unit (ICU)
treatment in northern Denmark between January 2010
and August 2017. We required ≥ 3 lactate measurements
between 6 h before until 24 h after ICU admission,
with ≥ 12 h between first and last measurement. Patients
receiving dialysis before ICU admission were excluded.
Metformin use was defined as a filled prescription for
metformin within 90 days before ICU admission [4]. CKD
stage was assessed by the mean estimated glomerular filtra-
tion rate (eGFR) 365 days until 7 days before ICU admission
[5]. Acute kidney injury (AKI) within 24 h after ICU admis-
sion was defined and staged according to the KDIGO cre-
atinine criteria. Lactate trajectories over time for metformin
users and nonusers were fitted by a mixed-effects model as-
suming unstructured covariance and including individual-
level random intercept and slope. Time was modeled as a
natural cubic spline with knot locations at − 1 h, + 4 h, and
+ 12 h relative to ICU admission. Time-by-group interaction
was entered as a covariate, and analyses were subsequently
stratified by eGFR level or AKI stage. Differences in max-
imum lactate level with 95% confidence intervals between
metformin users and nonusers were model-based.
We studied 20,741 patients with a total of 209,394 lactate
measurements, of whom 1905 (9%) patients used metfor-
min (Table 1). Compared with nonusers, metformin users
had a similar preadmission eGFR but had more often AKI
stage 2 or 3. Metformin users had 0.61 (0.45–0.77) mmol/
L higher maximum lactate levels than nonusers (Fig. 1a).
This difference was highest for patients with eGFR ≤ 45
ml/min/1.73m2 (1.06 [0.72–1.39] mmol/L; Fig. 1b). Differ-
ences in maximum lactate levels between metformin users
and nonusers were more pronounced in patients with AKI
stage 2 or 3 (Fig. 1c), with a difference of 0.30 (0.15–0.45)
mmol/L for patients without AKI, and 0.12 (− 0.24 to 0.48),
1.00 (0.35–1.65), and 1.75 (1.03–2.47) mmol/L among pa-
tients with AKI stage 1, 2, or 3, respectively. The difference
between metformin users and nonusers disappeared within
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24 h of ICU admission. However, the time until this differ-
ence disappeared was longer for patients with moderate to
severe CKD or AKI (Fig. 1).
In this large cohort of critically ill patients, metformin
users had higher lactate levels than nonusers in the early
phase of critical illness, which disappeared within 24 h of
ICU admission. Importantly, the difference in lactate levels
between metformin users and nonusers was higher in
patients with more severe AKI, while the difference was
almost similar across preadmission eGFR subgroups. This
may be explained by reduced clearance of metformin or
lactate, or both. A limitation is that blood metformin
Table 1 Characteristics of metformin users and nonusers
Characteristic Total (N = 20,
741)
Metformin users (N =
1905)
Metformin nonusers (N = 18,
836)
SMD*
Age, median [IQR], years 69 [58–77] 70 [63–76] 69 [58–77] 0.24
Male sex 11,697 (56) 1193 (63) 10,504 (56) 0.14
Charlson Comorbidity Index 0.52
0 6894 (33) 305 (16) 6589 (35)
1 or 2 8147 (39) 737 (39) 7410 (39)
3 or higher 5700 (27) 863 (45) 4837 (26)
Diabetes mellitus 4594 (22) 1903 (100) 2691 (14) 3.45
Sulfonylureas 476 (2) 250 (13) 226 (1) 0.48
Insulin 1473 (7) 443 (23) 1030 (5) 0.52
Other antihyperglycemic agents 445 (2) 259 (14) 186 (1) 0.50
Preadmission eGFR, median [IQR], ml/min/1.73m2 80 [58–95] 77 [58–92] 80 [58–95] 0.07
≥ 60ml/min/1.73 m2 12,892 (62) 1345 (71) 11,547 (61) 0.48
45–60ml/min/1.73 m2 2189 (11) 278 (15) 1911 (10)
≤ 45ml/min/1.73 m2 2442 (12) 221 (12) 2221 (12)
Missing 3218 (16) 61 (3) 3157 (17)
ICU admission type 0.20
Medical 9942 (48) 1019 (53) 8923 (47)
Emergency surgical 6344 (31) 456 (24) 5888 (31)
Elective surgical 3149 (15) 345 (18) 2804 (15)
Missing 1306 (6) 85 (4) 1221 (6)
Time from hospital admission to ICU admission, median
[IQR], h†
5.1 [0.0–30.5] 5.3 [0.0–29.4] 5.1 [0.0–30.7] 0.06
SAPS-II score, median [IQR] 40 [30–52] 42 [31–53] 40 [30–52] 0.09
Missing 11,456 (55) 1024 (54) 10,432 (55)
Mechanical ventilation 9305 (45) 815 (43) 8490 (45) 0.05
Inotropes or vasopressors 8943 (43) 854 (45) 8089 (43) 0.04
Renal replacement therapy 1257 (6) 152 (8) 1105 (6) 0.09
AKI stage within 24 h 0.47
No AKI 10,597 (51) 982 (52) 9615 (51)
1 3584 (17) 388 (20) 3196 (17)
2 1436 (7) 198 (10) 1238 (7)
3 1877 (9) 261 (14) 1616 (9)
Missing 3247 (16) 76 (4) 3171 (17)
30-day mortality 4367 (21) 346 (18) 4021 (21) 0.08
Data are expressed as no. (%) or median [IQR]
*As general guidance, it is suggested that effect sizes are likely to be “small” when an SMD approximates 0.2, likely to be “medium” when an SMD is 0.5, and
“large” when an SMD is higher than 0.8
†In total, data are missing for 19 (0.1%) patients
SMD standardized mean difference, eGFR estimated glomerular filtration rate, ICU intensive care unit, SAPS-II Simple Acute Physiology Score II, AKI acute
kidney injury
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concentrations were unavailable to confirm this be-
cause such correlation was found in patients receiving
renal replacement therapy for metformin-associated
lactic acidosis [6].
The monitoring of lactate trajectories is recommended
during critical illness [3]. Awareness of factors affecting
this biomarker will improve its interpretation. We report
that the association of metformin use with increased lac-
tate levels is more pronounced in patients who develop
AKI stage 2 or 3 than in patients without AKI or who
develop AKI stage 1.
Abbreviations
CKD: Chronic kidney disease; ICU: Intensive care unit; eGFR: Estimated
glomerular filtration rate; AKI: Acute kidney injury; KDIGO: Kidney Disease
Improving Global Outcomes; SMD: Standardized mean difference
Acknowledgements
We want to thank Trine Frøslev, MSc (Department of Clinical Epidemiology,
Aarhus University Hospital, Aarhus, Denmark), for the acquisition of data and
Daan J. Touw, PharmD, PhD (Department of Clinical Pharmacy and
Pharmacology, University Medical Center Groningen, Groningen, The
Netherlands), for interpretation of data and critically revising the manuscript
for important intellectual content. Both received no additional compensation
for the work provided.
Authors’ contributions
All authors contributed to the study conception and design, and analysis
and/or interpretation of the data. RAP, AH, and CFC collected data and
performed the analyses. RAP wrote the first draft of the manuscript. All
authors critically reviewed and edited the manuscript, and all authors read
and approved the final version. RAP and CFC had full access to all of the
data in the study and take responsibility for the integrity of the data and the
accuracy of the data analysis.
Funding
RAP was supported by a grant from the Aarhus University Research Fund
and the Van Leersum Grant of the Royal Netherlands Academy of Arts and
Sciences. AH received support provided by the Steno Diabetes Center
Aarhus, which is partially funded by an unrestricted donation from the Novo
Nordisk Foundation. The funder had no role in the design and conduct of
the study; collection, management, analysis, and interpretation of the data;
preparation, review, or approval of the manuscript; and decision to submit
the manuscript for publication.
Availability of data and materials
Parts of the data that support the findings of this study are available from
the Danish Health Data Authority (Sundhedsdatastyrelsen), but restrictions
apply to the availability of these data, which were used under license for the
present study and are thus not publicly available.
Fig. 1 Lactate levels for metformin users and nonusers according to estimated glomerular filtration rate and acute kidney injury stage. Mean
lactate trajectories over time with 95% confidence interval for metformin users and nonusers were fitted by a mixed-effect model with individual-
level random intercept and slope. Time after ICU admission was modeled as natural cubic spline with knot location at − 1 h, + 4 h, and + 12 h
surrounding intensive care unit admission. a Total population. Subsequently, analyses were stratified according to b chronic kidney disease stage
based on mean estimated glomerular filtration rate (eGFR) 1 year before ICU admission or c acute kidney injury (AKI) stage within 24 h of
ICU admission
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